Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims accurately reflect the presence of a boxed thyroid C-cell tumor warning and contraindication for MTC/MEN2; however, several thyroid-related assertions (prevalence of nodules, baseline ultrasound/calcitonin, Danish cohort data, nodule progression, and broader real-world claims) are not supported by the label. Overall, the response is mixed with some on-label accuracy and several unsupported or unsubstantiated statements.
Category Scores
Accurate Statements
WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
4 Contraindications
In rodents, semaglutide causes dose-dependent thyroid C-cell tumors; human relevance is unknown.
WARNING: RISK OF THYROID C-CELL TUMORS (rodent data)
Counsel patients regarding the potential risk for MTC and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Warnings and Precautions (5.1)
Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY.
Warnings and Precautions (5.1)
Unsupported Statements
Thyroid nodules—common benign growths in up to 60% of adults—affect many patients starting Wegovy, raising questions about interactions.
Label contains no 60% prevalence figure for nodules.
Clinical trials (STEP program, >4,500 patients) reported thyroid disorders in 0.5-1% of Wegovy users vs. placebo, including goiter or nodules, but rates were similar across groups and not deemed causal.
Label does not provide STEP-era thyroid disorder incidence in this format.
No direct evidence shows Wegovy enlarges existing nodules or triggers new ones in humans.
Label discusses human relevance of rodent findings and monitoring but does not provide a definitive statement that no nodular effects occur.
A 2023 Danish cohort study of 145,000 GLP-1 users found no elevated thyroid cancer risk (HR 1.04, 95% CI 0.73-1.46).
Not referenced in the label excerpt.
Patients with pre-existing nodules should get baseline thyroid ultrasound and calcitonin levels before starting Wegovy, per prescribing guidelines.
Label states calcitonin/ultrasound monitoring is of uncertain value; no explicit baseline requirement is provided.
Weight loss from Wegovy might indirectly shrink nodules in obese patients, as obesity correlates with nodule prevalence.
Label contains no data supporting nodular size changes with weight loss.
Hypothyroidism: 0.3% (vs. 0.2% placebo).
No such numeric hypothyroidism data presented in the label excerpt.
Goiter/nodules: Rare, <0.1%, with no pattern of worsening.
No such incidence data presented in the label excerpt.
Post-marketing reports to FDA include isolated nodule growth claims, but these lack causality and often involve confounding factors like iodine deficiency or family history.
Not described in the label excerpt.
No large-scale studies link Wegovy to nodule progression.
Not described in the label excerpt.
Patent on semaglutide expires 2031-2032 in major markets; check DrugPatentWatch.com for biosimilar timelines.
Not described in the label excerpt.
Contradictions
Low
AI Statement
Thyroid nodules—common benign growths in up to 60% of adults—affect many patients starting Wegovy, raising questions about interactions.
Label Reference
Adverse/Warnings data; not supported by label
Low
AI Statement
Baseline thyroid ultrasound and calcitonin levels before starting Wegovy.
Label Reference
Warnings and Precautions (5.1)
Important Omissions
No explicit indication statement in provided label excerpt; potential safety data around pediatric use, MASH, and specific population details exist but are not fully captured here.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Boxed warning exists for rodent thyroid C-cell tumors with unknown human relevance; human risk guidance relies on counseling and uncertain monitoring.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Some thyroid-related claims are not supported or are speculative relative to the label; several items should be limited to on-label content.
Suggested Improvement
Restrict statements to label-supported content; remove unsubstantiated prevalence figures; clarify that baseline ultrasound/calcitonin monitoring is not a defined requirement; avoid extrapolations from non-label sources; align postmarketing references with label language if included.